Aon's analysis of 139,000 employees reveals that while GLP-1 diabetes and weight-loss drugs (like Mounjaro, Ozempic, and Wegovy) initially increase healthcare costs, they yield significant long-term savings. After two years, overall healthcare costs for patients fell 7%, reaching up to 13% for those with high adherence. The study highlights a 44% reduction in major cardiovascular events and substantial decreases in osteoporosis and pneumonia. Despite high upfront costs, Aon projects a positive return on investment, prompting them to launch a subsidized GLP-1 program for their employees.

Prepared by Olivia Bennett and reviewed by editorial team.